Le Lézard
Classified in: Health
Subject: MAT

GVB Biopharma Taken Private, Poised for Continued Growth in Hemp and Cannabis Industry


PRINEVILLE, Ore., Jan. 3, 2024 /PRNewswire/ -- GVB Biopharma, a pioneer in the hemp and cannabis industry, is thrilled to announce its transition back to a private entity controlled by its founding team as of December 28th, 2023. Acquired by NASDAQ listed 22nd Century Group in May 2022, this strategic move marks a new chapter in GVB's story.

As a privately-held company, GVB Biopharma is uniquely positioned to leverage its industry-leading expertise in research, genetics, and proprietary technologies. This transition allows for a more agile approach in meeting the evolving needs of the global hemp and cannabis markets, while pursuing ambitious growth and excellence in serving its customers.

GVB Biopharma remains at the forefront of the industry with its cutting-edge cryogenic hemp extraction methods, refining, conversion, and advanced product formulation technologies. As a leading supplier of cannabinoids, GVB is committed to maintaining its reputation for high-quality, trusted products.

"As the hemp industry continues to mature, our vision and capabilities align perfectly with the market's direction," said Drew Spiegel, Chief Executive Officer of GVB Biopharma. "We are excited to lead the charge in this next phase of industry growth, driven by our commitment to quality, innovation, and our valued customers."

About GVB Biopharma
GVB Biopharma is a world leader in the hemp and cannabis sector, specializing in research, genetics, proprietary extraction, refining, and product formulation technologies. The company offers an unparalleled range of high-quality products and services, backed by robust manufacturing capabilities and a deep understanding of regulatory landscapes. As a trusted partner in the global hemp industry, GVB Biopharma is dedicated to advancing wellness and health through its innovative solutions.

Contact:
Sebastian Ravitz
Chief Marketing Officer
(801) 203-0887
[email protected]
gvbbiopharma.com

SOURCE GVB Biopharma


These press releases may also interest you

at 05:23
The revenue in June for Zinzino's sales markets increased by 13% and amounted to SEK 148.5 (131.4) million. Faun Pharma's external sales decreased and amounted to SEK 5.8 (8.5) million. Overall, the Group increased revenues by 10% to SEK 154.3...

at 05:00
The global Specialty Enzymes Market size is estimated to be valued at USD 6.1 billion in 2024 and is projected to reach USD 9.2 billion by 2029, recording a CAGR of 8.5% from 2024 to 2029 according to a report published by MarketsandMarketstm. The...

at 05:00
Kvantify, a leading quantum software start-up, has announced the successful closure of a EUR 10 million seed round. This funding will enable Kvantify to strengthen its position as a global leader in quantum computing, with an initial focus on...

at 04:37
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cytotoxic Drugs and HPAPI Manufacturing  Market- (Type of Product (HPAPI and highly potent finished dosage form), Company Size (Small, Mid-sized, Large,...

at 04:32
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC...

at 04:32
The Compound Annual Growth Rate (CAGR) measures how much an investment grows each year, on average, over a period. It helps to show the overall trend by smoothing out the ups and downs. Recently, BCC Research predicted that a certain industry would...



News published on and distributed by: